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Human Xenograft Models for Virus Infection
Donald E. Mosier1
Department of Immunology, The Scripps Research Institute, La Jolla, California 92037Received February 10, 2000; accepted April 3, 2000The transplantation of human cells or tissues to se-
verely immunodeficient strains of mice was first shown
to allow engraftment of normal (as opposed to trans-
formed) cells more than a decade ago (Kamel-Reid and
Dick, 1988; Lubin et al., 1991; McCune et al., 1988; Mosier
t al., 1988). Early studies using these models focused on
uman immunodeficiency virus (HIV-1) and Epstein–Barr
irus (EBV) infection, but many viruses have been the
ubject of more recent studies in xenografted SCID mice
see Table 1). Engraftment of fetal hematopoietic tissues
nto SCID-hu mice has permitted the study of T cell
ifferentiation and HIV-1 infection of immature as well as
ature lymphoid cells (Aldrovandi et al., 1993; Bonyadi et
l., 1993). Transfer of peripheral blood mononuclear cells
o hu-PBL-SCID mice has allowed the study of HIV-1
nfection of mature lymphoid cells (Mosier et al., 1991,
993; Picchio et al., 1998) as well as the understanding of
ome aspects of the immune response to infection (Mc-
inney et al., 1999; Poignard et al., 1999). Transplantation
of HIV-infected cells into the brains of SCID mice has
reproduced some aspects of CNS infection in humans
(Avgeropoulos et al., 1998; Persidsky et al., 1999; Sanders
et al., 1998). Recent studies of HIV-1 infection in hu-PBL-
SCID or SCID-hu mice have provided important insights
into virus immunity, target cells for virus infection, and
suppression of hematopoietic progenitors. These stud-
ies will be briefly summarized here.
PASSIVE IMMUNITY TO HIV-1
Previous studies have demonstrated that passive
transfer of neutralizing antibody to hu-PBL-SCID mice
prior to HIV-1 challenge can protect against infection
(Gauduin et al., 1995, 1997; Parren et al., 1995), although
relatively high concentrations of antibody (e.g., 50 mg/kg)
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215are required for protection against primary, R5 isolates
(Gauduin et al., 1997). Similar protective effects have
been reported in SCID-hu mice (Okamoto et al., 1998).
One additional report showed protection of hu-PBL-SCID
mice by a monoclonal antibody (B4) directed to a recep-
tor complex when administered at 5 mg/kg up to 4 h after
virus challenge (Wang et al., 1999). Two recent reports
show that neutralization escape mutants can rapidly
emerge if neutralizing antibody levels fall below protec-
tive levels. A neutralization escape variant of the chal-
lenge LAI isolate was selected in hu-PBL-SCID mice
pretreated with 13.2 mg/kg of a V3-directed monoclonal
antibody (Andrus et al., 1998). A second report showed
that passive antibody treatment of hu-PBL-SCID mice
with preexisting infection with the R5 JR-CSF primary
isolate generated neutralization escape variants even
when a cocktail of three potent neutralizing antibodies
was administered (Poignard et al., 1999). Mice were
treated with 50 mg/kg of IgG-b12, 2F5, and 2G12 human
monoclonal antibodies against three distinct epitopes on
gp120 and gp41. Virus recovered from one treated animal
showed mutations altering all three epitopes, and the
virus was now resistant to in vitro neutralization with the
antibody cocktail. Neutralization-sensitive virus reap-
peared in this animal when monoclonal antibody levels
declined below 200 mg/ml. This finding suggests that
very high antibody levels are necessary to exert selective
pressure on virus replication and that the unmutated
starting virus had a fitness advantage over the neutral-
ization escape mutant. These findings raise concern that
candidate HIV-1 vaccines will need to provide sterilizing
immunity since anything less appears to allow the gen-
eration of neutralization escape variants.
Passive cellular immunotherapy of HIV-1 infection in
the hu-PBL-SCID model has demonstrated both the
promise and the potential problems with this approach.
Transfer of gag-specific CTL clones derived from an
infected twin to hu-PBL-SCID mice reconstituted with
cells from the uninfected identical twin resulted in tran-
sient declines in plasma viral RNA levels (McKinney et
0042-6822/00 $35.00
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216 MINIREVIEWal., 1999). The fate of the injected CTL was followed
using cells labeled with carboxyfluoroscein succinimide
ester (CFSE). CTL specific for an unrelated antigen
showed greater than 90% survival 1 week after injection
into HIV-infected animals, but gag-specific CTL showed
rapid elimination within 3 days of injection. Poor survival
of adoptively transferred CTL has also been observed in
human studies (Brodie et al., 1999; Tan et al., 1999).
ffective immunotherapy with CTL will have to circum-
ent this problem of poor survival, which may be caused
y target cell-induced killing of CTL, as well as other
ecognized limitations such as epitope escape mutations
Borrow et al., 1997; Koenig et al., 1995). Cotransfer of
D41 T cells may enhance CTL activity or longevity. A
ecent study reported promising results from the transfer
f human CD41 T cells expressing interferon-beta into
IV-1-infected hu-PBL-SCID mice (Vieillard et al., 1999).
nterferon-expressing cells were selectively spared from
IV-1 infection and were able to eliminate virus infection
n 40% of animals. Transduction of HIV-1-specific CD41 T
ells with type 1 interferon may be able to protect them
rom infection and allow enhanced CTL activity.
These experiments demonstrate that effective immu-
ity against HIV-1 will be difficult to achieve. The xeno-
raft models offer a method for testing new approaches
o generate more effective and durable immunity. Two
ecent reports also suggest the potential for developing
rimary immune responses to HIV-1 antigens in modified
odels of hu-PBL-SCID (Delhem et al., 1998) or SCID-hu
mice (Carballido et al., 2000).
TARGET CELLS FOR HIV-1 INFECTION
T
Virus Infections Studied in SC
Virus Model Target cells
HIV Both CD41 cells
BV Hu-PBL-SCID B cells
CMV SCID-hu Thymic epithelium
HHV6 SCID-hu Thymocytes
HHV8 SCID-hu B cells
Measles Both Thymocytes/T cells
Varicella zoster SCID-hu T cells, skin
HSV-1 SCID-hu T cells, skin
Dengue Cell line-SCID HepG2, K562
Papillomavirus Cervical biopsies Epithelial
Hepatitis B Trimera (hu-PBL-
SCID)
Liver
Hepatitis C Hu-PBL-SCID B cellsIt is now widely appreciated that HIV-1 can be divided
into strains that use CCR5 as a coreceptor for virus entry,strains that use CXCR4 as a coreceptor, and dual-tropic
strains that can use either. The shorthand nomenclature
for these virus subtypes are R5, X4, and R5X4 (Berger et
al., 1998). This means that target cells for virus infection
must express the appropriate coreceptor to be permis-
sive for virus entry. Studies in xenografted SCID mice as
well as tonsil histocultures (Glushakova et al., 1997) have
demonstrated that R5 and X4 HIV-1 isolates have differ-
ent targets and different kinetics of infection. Infection of
hu-PBL-SCID mice with R5 strains produces a prolonged
infection with slow depletion of CD41 T cells, and infec-
tion with X4 or R5X4 strains causes a shorter course of
infection with rapid depletion of CD41 cells (Picchio et
al., 1998). As illustrated in Fig. 1, only a fraction of acti-
hy/Liv or hu-PBL-SCID Mice
Outcome References
Cell depletion Namikawa et al. (1988), Mosier et al.
(1991), Bonyadi et al. (1993),
Aldrovani et al. (1993)
Lymphoproliferative
disease
Picchio et al. (1992), Rowe et al. (1990)
Viral persistence Mocarski et al. (1993)
Cell depletion Gobbi et al. (1999)
Viral persistence Dittmer et al. (1999)
Cell depletion,
immunosuppression
Tishon et al. (1996), Valsamakis et al.
(1998)
Selective replication Moffat et al. (1998a,b)
Selective replication Moffat et al. (1998a)
Death of mice An et al. (1999), Lin et al. (1998)
Viral persistence,
cytopathology
Taylor et al. (1999)
Viral persistence Ilan et al. (1999)
Viral persistence Bronowicki et al. (1998)
FIG. 1. Virus and target cell subpopulations in HIV-1 infection. R5
viruses can infect cells bearing CCR5, which is a rapidly cycling subset
of all CD41 target cells. The R5 virus subset dominates after primary
nfection, as is indicated by the larger diameter of the R5 virus symbol.
5X4 and X4 viruses (indicated here by only X4) are a smaller popu-
ation and target a larger pool of target cells. Naive CD41 T cells are
1 2ABLE 1
ID-hu TCXCR4 and CCR5 , and their turnover is slower than that of activated
memory cells, which express both CXCR4 and CCR5.
c
c
m
a
p
a
t
e
d
217MINIREVIEWvated CD41 T cells express CCR5, so the pool of target
ells is smaller for R5 viruses. Expression of CCR5 in-
reases with time after grafting of human cells into SCID
ice, whereas CXCR4 is expressed on both naive and
ctivated CD41 T cells and its expression is constant
with time (Fais et al., 1999). This explains the finding that
hu-PBL-SCID mice are more susceptible to X4 viruses
early after grafting but more susceptible to R5 viruses at
2 or more weeks after grafting (Fais et al., 1999). R5
strains are also less pathogenic for fetal thymus grafts in
the SCID-hu model (Berkowitz et al., 1998a,b), even if the
R5 isolates are derived from rapid progressors (Berko-
witz et al., 1999). However, CCR51 cells are rapidly de-
leted by R5 strains (Grivel and Margolis, 1999; Penn et
l., 1999), so it is the restriction in target cell availability
hat limits the spread of R5 isolates. There is some
vidence that X4 or R5X4 isolates cause additional cell
eath in uninfected bystanders (Herbein et al., 1998;
Maldarelli et al., 1995), but it is probably incorrect to
consider R5 isolates noncytopathic. Figure 1 also illus-
trates that target cell populations expressing CCR5 and
CXCR4 differ in both size and turnover rates, with acti-
vated memory cells expressing CCR5 having a faster
turnover than the total pool of naive and memory cells
expressing CXCR4. This means that models of cell turn-
over in HIV-1 infection must consider the coreceptor use
of the virus, which is known to evolve over time (Shan-
karappa et al., 1999).
HIV SUPPRESSION OF HEMATOPOIESIS
Infection with HIV-1 is known to suppress develop-
ment of all hematopoietic lineages in a sizable fraction of
patients, but there has been a long controversy about the
mechanism of suppression. Since primitive hematopoi-
etic progenitors express low levels of CD4 and CXCR4
(Aiuti et al., 1999; Peled et al., 1999), they could be direct
targets for virus infection. However, several lines of evi-
dence from experiments in SCID-hu mice have con-
verged to suggest that the mechanism of HIV-1 suppres-
sion is indirect. Infection of fetal thymus 1 liver grafts
suppresses colony-forming activity and generation of
thymocyte precursors, yet there is no evidence that
CD341 progenitor cells are infected (Jenkins et al., 1998;
Koka et al., 1999). CD341 cells lacked proviral DNA and
were not marked by a reporter virus. One report suggests
that TNF-alpha production may mediate the indirect sup-
pression of hematopoietic progenitors (Yurasov et al.,
1999). Antiviral therapy can reverse this suppression and
allow the differentiation of endogenous or exogenous
progenitors (Amado et al., 1999). These results suggest
that suppression of hematopoiesis during HIV-1 infection
is due to indirect mechanisms and is reversible if viral
replication is controlled.FUTURE DIRECTIONS
It now appears that development of transgenic mice
that are fully permissive for HIV-1 replication faces sev-
eral obstacles beyond virus entry and that “simple” ani-
mal models for HIV-1 infection (other than SIV or SHIV
infection of primates) will not be available for some time.
Ongoing technical improvements in xenotransplant mod-
els may render them more useful, and their susceptibility
to infection with a wide range of viruses makes them
appropriate tools for many important studies. Preliminary
success in hepatocyte transplantation into immunodefi-
cient mice (Petersen et al., 1998) suggests the possibility
of better models for hepatitis B and hepatitis C virus
infection.
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